(NASDAQ:SUNW) to report $-0.02 EPS on April, 4.They anticipate $0.16 EPS change or 88.89% from last quarter's $-0.18 EPS.
However looking at valuation ratios the stock has 5 year expected PEG ratio of 0 whereas its trailing twelve month P/E ratio is 0. The stock increased 2.69% or $0.72 during the last trading session, reaching $27.45. About 1.15 million shares traded. It has underperformed by 1.14% the S&P500. Flexion Therapeutics has $44 highest and $28.0 lowest target. The company has market cap of $1.00 billion. The institutional investor held 1.18 million shares of the health care company at the end of 2017Q3, valued at $28.56M, up from 527,800 at the end of the previous reported quarter. It dived, as 13 investors sold Flexion Therapeutics, Inc. shares while 28 reduced holdings. The stock increased 1.38% or $0.8 during the last trading session, reaching $58.75. About 98,220 shares traded. Flexion Therapeutics (NASDAQ:FLXN)'s price sits 8.92% above from its 50-day moving average of $24.25 and 14.58% far from the stock's 200-day moving average which is $24.49. Its down 0.99% from 9.96M shares previously. BidaskClub upgraded shares of Flexion Therapeutics from a "strong sell" rating to a "sell" rating in a research note on Wednesday, February 28th. Therefore 100% are positive. BMO Capital Markets maintained Flexion Therapeutics, Inc.More news: Send your name to the sun with Nasa's groundbreaking space probe
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The stock has "Outperform" rating by BMO Capital Markets on Monday, October 9. The rating was initiated by Lake Street with "Buy" on Thursday, July 21. The rating was maintained by RBC Capital Markets on Friday, July 7 with "Buy". The firm has "Buy" rating given on Wednesday, November 4 by Cantor Fitzgerald. The company was maintained on Monday, June 26 by BMO Capital Markets. The stock has "Hold" rating by Sandler O'Neill on Monday, May 9. The company was maintained on Wednesday, October 4 by Northland Capital. The firm earned "Outperform" rating on Tuesday, May 3 by Wells Fargo.
Investors sentiment decreased to 1.22 in 2017 Q3. Its up 1.85, from 1.22 in 2017Q2.More news: Ravens cut Webb, sign OL Hurst to $17.5 million deal
Want to see what other hedge funds are holding FLXN? Bnp Paribas Arbitrage Sa reported 2,759 shares or 0% of all its holdings. D E Shaw & Company has invested 0% in Flexion Therapeutics, Inc. Barclays Public Ltd Liability Co stated it has 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 936,507 shares. State Board of Administration of Florida Retirement System purchased a new position in Flexion Therapeutics during the third quarter worth about $235,000. Scholtz & Ltd Co holds 1.05% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) rating on Thursday, July 21. Tower Research Limited Liability (Trc) holds 561 shares. Flexion Therapeutics (NASDAQ:FLXN)'s price to free cash flow for trailing twelve months is 0. (NASDAQ:FLXN). Jpmorgan Chase And invested in 164,400 shares or 0% of the stock. Dupont Cap Management Corporation owns 0.01% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 73,339 shares. Jaffetilchin Inv Ptnrs Ltd Liability Com holds 10,592 shares or 0.22% of its portfolio. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company. Therefore 56% are positive.
FLXN has been the topic of a number of research analyst reports. They issued a buy rating and a $42.00 price target for the company. The stock of Flexion Therapeutics, Inc. (NASDAQ:FLXN) on Friday, March 9 with "Outperform" rating. The rating was maintained by RBC Capital Markets on Friday, July 7 with "Buy". The firm has "Market Perform" rating given on Thursday, June 23 by Raymond James. (NYSE:DHI) earned "Buy" rating by Keefe Bruyette & Woods on Tuesday, October 10. The company has market cap of $22.68 million.More news: Alibaba Group (NYSE:BABA) Stock Rating Upgraded by Vetr
Long Pond Capital Lp, which manages about $1.63B and $2.77 billion US Long portfolio, decreased its stake in La Quinta Hldgs Inc (NYSE:LQ) by 357,288 shares to 1.16 million shares, valued at $20.29 million in 2017Q3, according to the filing. It also increased its holding in Aetna Inc New (NYSE:AET) by 60,445 shares in the quarter, for a total of 130,334 shares, and has risen its stake in Powershares Qqq Trust (Put) (QQQ). The company has a debt-to-equity ratio of 0.58, a quick ratio of 12.96 and a current ratio of 13.02. Shares for $903,031 were sold by DOUGLAS MARK on Wednesday, February 14. (NYSE:DHI) on Wednesday, February 14. Shares for $143,213 were sold by Hewatt Michael W on Thursday, March 1.